Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluticasone furoate→

Fluticasone furoate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
397864-44-7
PubChem CID
9854489
Molecular formula
C27H29F3O6S
Molecular weight
538.6 g/mol
Drug class
Synthetic glucocorticoidintranasal/inhaled corticosteroid anti-inflammatory agent
Mechanism of action
Activates intracellular glucocorticoid receptors and suppresses inflammatory cytokines and mediator release in airway and nasal tissues. The clinical mechanism depends on the route and whether fluticasone furoate is used alone or in a fixed combination.
Indications / reported uses
  • Treatment of allergic rhinitis symptoms with intranasal fluticasone furoate products
  • Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) only in authorised fixed combinations with a long-acting bronchodilator; fluticasone monotherapy and combination-product indications are not interchangeable

Sources: US DailyMed — Fluticasone furoate nasal spray · US DailyMed — BREO ELLIPTA (fluticasone furoate/vilanterol) · FDA product information

Identification source: PubChem record (CID 9854489). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Synthetic glucocorticoid; intranasal/inhaled corticosteroid anti-inflammatory agent

Mechanism of action

Activates intracellular glucocorticoid receptors and suppresses inflammatory cytokines and mediator release in airway and nasal tissues. The clinical mechanism depends on the route and whether fluticasone furoate is used alone or in a fixed combination.

General use cases

  • Treatment of allergic rhinitis symptoms with intranasal fluticasone furoate products
  • Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) only in authorised fixed combinations with a long-acting bronchodilator; fluticasone monotherapy and combination-product indications are not interchangeable

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Fluticasone furoate Environmental Risk Assessment (ERA) (the Fluticasone furoate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.